Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

Consultation on draft scope – deadline for comments by 5pm on 26th September 2019

Email: safeprescribing@nice.org.uk

Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly or arrive after the deadline.

In addition to your comments below, we would like to hear your views on these questions:

1. Are there any cost saving interventions or examples of innovative approaches that should be considered for inclusion in this guideline?

Developing NICE guidance: how to get involved has a list of possible areas for comment on the draft scope.

<table>
<thead>
<tr>
<th>Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):</th>
<th>British HIV Association</th>
</tr>
</thead>
</table>

Disclosure

Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.

None

<p>| Name of person completing form: | Dr Nadi Gupta |</p>
<table>
<thead>
<tr>
<th>Comment No.</th>
<th>Page number</th>
<th>Line number</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4</td>
<td>1</td>
<td>Do we need to signpost to the HIV Liverpool drug interactions website and highlight it as a useful resource re safe prescribing in people living with HIV</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>19</td>
<td>What services can patients access themselves to assist with withdrawal of prescribed drugs? Signposting would be important. Would this be part of the information for patients? (section 3.34). I am not aware of any support services that exist for prescribed drug dependence (current services available seem to be for illegal drug use and those patients addicted to prescribed drugs may not identify/engage with services that deal with illegal drug dependence).</td>
</tr>
<tr>
<td>3</td>
<td>7</td>
<td>9</td>
<td>It would be most helpful to include the details of specific recommended regimes for each drug to assist with safe withdrawal. I presume this would be included here.</td>
</tr>
<tr>
<td>4</td>
<td>General</td>
<td>General</td>
<td>Does the scope need to include something about when to seek more specialist advice? i.e. where would the GP refer the more complex patients? Are there specialists in managing addiction specifically to prescribed drugs?</td>
</tr>
</tbody>
</table>

Checklist for submitting comments

- Use this form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include page and line number (not section number) of the text each comment is about.
- Combine all comments from your organisation into 1 response. We cannot accept
more than 1 response from each organisation.

- Do not paste other tables into this table – type directly into the table.
- Mark any confidential information or other material that you do not wish to be made public. Also, ensure that you state in your email to NICE that you have confidential comments included in your submission.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, do not include attachments such as research articles, letters or leaflets. We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments.
- **We do not accept comments submitted after the deadline stated for close of consultation.**

**Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.